Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alfa-2b and Structured Treatment Interruptions in HIV-Infected Patients
NCT00125814Phase 3Terminated
- Sponsor
- ANRS
- Start
- Dec 2001
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa-2b in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Proportion of patients who did not reach the criteria to resume antiretroviral treatment at 72 weeks. Started Dec 2001; status: terminated.
02
Drugs
interferon alfa-2b
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00125814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125814.